BMY vs NVO: stock comparison and AI forecast
Bristol Myers Squibb Co (BMY) and Novo Nordisk A S (NVO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMY Bristol Myers Squibb Co
- Price
- $62.14 +10.5% · 6M
- Market Cap
- $127.02B
- P/E Ratio
- 13.8x
- Size
- large-cap
- AI Forecast
NVO Novo Nordisk A S
- Price
- $40.31 -12.0% · 6M
- Market Cap
- $179.14B
- P/E Ratio
- 3.0x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- NVO is 1.4 times larger than BMY by market capitalization ($179.14B against $127.02B).
- NVO trades at 3.0 times trailing earnings, BMY at 13.8 times.
- Over the last six months BMY returned +10.5% and NVO -12.0%.
- NVO turns 34.0% of its revenue into net income, against 18.5% for BMY.
- BMY carries 2.79 times debt per unit of equity, against 1.80 times for NVO.
- BMY yields 4.03% in dividends; NVO pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMY | NVO |
|---|---|---|
| Market Cap | $127.02B | $179.14B |
| P/E Ratio | 13.75x | 2.99x |
| P/B Ratio | 5.43x | – |
| Dividend Yield | 4.03% | – |
| EPS | $4.52 | $13.48 |
| Book Value/Share | $11.45 | – |
| Revenue/Share | $24.48 | $34.48 |
| FCF/Share | $4.54 | $9.66 |
Profitability & Margins
| Metric | BMY | NVO |
|---|---|---|
| ROE | 39.5% | 176.6% |
| ROA | 10.4% | 63.1% |
| ROIC | – | 132.4% |
| Gross Margin | 69.2% | 83.4% |
| Operating Margin | – | 43.0% |
| Net Margin | 18.5% | 34.0% |
| EBT Margin | 22.6% | 42.8% |
| Tax Rate | 18.4% | 20.6% |
Financial Health
| Metric | BMY | NVO |
|---|---|---|
| Current Ratio | 1.59x | 0.80x |
| Quick Ratio | 1.44x | 0.57x |
| D/E Ratio | 2.79x | 1.80x |
| Financial Leverage | 3.79x | 2.80x |
| Interest Coverage | 42.5x | – |
| Working Capital | $11.01B | -$6.79B |
Cash Flow
| Metric | BMY | NVO |
|---|---|---|
| Operating Cash Flow | $10.65B | $64.99B |
| Free Cash Flow | $9.29B | $42.93B |
| Capital Spending | -$1.37B | -$22.06B |
| OCF Growth YoY | -35.9% | 115.7% |
| FCF Growth YoY | -39.3% | 0.0% |
| FCF/Sales | 18.6% | 28.0% |
| CapEx/Sales | 2.7% | 14.4% |
Operational Efficiency
| Metric | BMY | NVO |
|---|---|---|
| Asset Turnover | 0.56x | 1.86x |
| Receivables Turnover | 5.4x | – |
| Inventory Turnover | 5.7x | 3.4x |
| Fixed Assets Turnover | 6.3x | – |
| Days Sales Outstanding | 67 days | – |
| Days Inventory | 64 days | 108 days |
| Payables Period | 110 days | – |
| Cash Conversion Cycle | 21 days | – |
Income Statement
| Metric | BMY | NVO |
|---|---|---|
| Total Revenue | $50.03B | $153.22B |
| Operating Income | – | $65.83B |
| Net Income | $9.24B | $52.04B |
| R&D Expense | $10.56B | $23.79B |
| SG&A Expense | $7.32B | – |
| Cost of Goods Sold | $15.39B | $25.45B |
Dividend & Shareholder Information
| Metric | BMY | NVO |
|---|---|---|
| Dividends Per Share | $2.50 | – |
| Payout Ratio | 55.3% | – |
| Shares Outstanding | 2044M | 4444M |
| Net Income Growth | 53.1% | 104.6% |
| EPS Growth | 52.2% | 24.9% |
BMY vs NVO: stock comparison and AI forecast
Which is bigger, BMY or NVO?
NVO is 1.4 times larger than BMY by market capitalization ($179.14B against $127.02B).
Which is cheaper on earnings, BMY or NVO?
NVO trades at 3.0 times trailing earnings, BMY at 13.8 times.
Which stock performed better over the last six months, BMY or NVO?
Over the last six months BMY returned +10.5% and NVO -12.0%.
Which one does Intratio's AI model rank higher, BMY or NVO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.